We investigated the role of single nucleotide polymorphisms in genes encoding for drug-metabolizing enzymes in 209 newly diagnosed multiple myeloma patients included in a clinical trial comparing single with double intensive therapy. We observed no significant association between polymorphisms in CYP3A4, CYP3A5, MDR1, GSTM1 and GSTT1 and outcome either after treatment with induction chemotherapy or after high-dose therapy.

, , ,
doi.org/10.3324/haematol.10618, hdl.handle.net/1765/36131
Erasmus MC: University Medical Center Rotterdam

Schilthuizen, C., Broyl, A., van der Holt, B., de Knegt, Y., Lokhorst, H., & Sonneveld, P. (2007). Influence of genetic polymorphisms in CYP3A4, CYP3AS, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma. Haematologica, 92(2), 277–278. doi:10.3324/haematol.10618